Bullfrog AI Holdings Inc（BFRG）資訊與事件BFRGBullfrog AI Holdings Inc

BullFrog AI Achieves Key Milestones with Global Pharmaceutical Company

BullFrog AI announced it has achieved project milestones under its commercial program with a global pharmaceutical company. BullFrog AI successfully identified and prioritized novel therapeutic targets for major depressive disorder by applying its platform to proprietary neuropsychiatric multi-omic data sets. As a core component of its commercial strategy, BullFrog AI is also applying its technology to the discovery and development of novel drug targets for a range of other neuropsychiatric diseases, including schizophrenia and bipolar disorder. BullFrog AI believes there is significant opportunity to scale the application of its technology to other therapeutic areas of high patient impact through deep analysis of biomedical datasets. "We've achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets," said BullFrog AI founder and CEO Vin Singh. "We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets."

Selling Stockholder Plans to Sell Up to 2M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholder of up to 2M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

BullFrog AI Secures Financial Runway Until Late 2027

BullFrog AI issued a letter to shareholders from founder and CEO Vin Singh stating the company has secured the financial runway to execute its strategy into late 2027 and is in active discussions with pharmaceutical and biotechnology organizations. "BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations," said Vin Singh, founder and CEO. "We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late 2027, and are deeply engaged with an industry that is no longer evaluating whether to embrace AI-driven drug discovery - but deciding with whom".